肿瘤研究与临床
腫瘤研究與臨床
종류연구여림상
CANCER RESEARCH AND CLINIC
2014年
1期
48-51
,共4页
李鹏%刘立成%吴欣%徐文通
李鵬%劉立成%吳訢%徐文通
리붕%류립성%오흔%서문통
胃肠道间质肿瘤%外科手术%伊马替尼%预后
胃腸道間質腫瘤%外科手術%伊馬替尼%預後
위장도간질종류%외과수술%이마체니%예후
Gastrointestinal stromal tumors%Surgical procedures,operative%Imatinib%Prognosi
目的 探讨胃间质瘤患者生存情况以及手术治疗和药物治疗对患者生存的影响.方法 回顾性分析2003年1月至2013年1月具有完整病理及随访资料的132例原发胃间质瘤患者的临床特点及生存情况.结果 132例患者术后中位随访22个月(1～83个月),1、3、5年的生存率分别为99％、96％、92％.肿瘤位于贲门19例(14.4％),胃底34例(25.8％),胃大弯38例(28.8％),胃小弯38例(28.8％),胃窦3例(2.3％).其中CD117+116例(87.9％),CD34+119例(90.2％),Ki-67+ 51例(38.6％).按照Fletcher分级,极低生物学风险者10例(7.6％),低风险者34例(25.8％),中风险者14例(10.6％),高风险者74例(56.1％).Fletcher风险分级极低风险患者的1、3、5年生存率均为100％,低风险患者均为97％,中风险患者均为92％,高风险患者分别为96％、88％、83％,差异有统计学意义(P=0.028).完全切除+伊马替尼组患者1、3、5年生存率均为100％,完全切除未服用伊马替尼组患者均为99％,非完全切除+伊马替尼组患者分别为89％、65％、48％,差异有统计学意义(P＜0.05);不同解剖分区的胃间质瘤患者生存率差异无统计学意义(P＞0.05).结论 不同解剖部位的胃间质瘤患者预后无明显不同,手术完整切除肿瘤和术后服用伊马替尼可改善患者预后.
目的 探討胃間質瘤患者生存情況以及手術治療和藥物治療對患者生存的影響.方法 迴顧性分析2003年1月至2013年1月具有完整病理及隨訪資料的132例原髮胃間質瘤患者的臨床特點及生存情況.結果 132例患者術後中位隨訪22箇月(1～83箇月),1、3、5年的生存率分彆為99％、96％、92％.腫瘤位于賁門19例(14.4％),胃底34例(25.8％),胃大彎38例(28.8％),胃小彎38例(28.8％),胃竇3例(2.3％).其中CD117+116例(87.9％),CD34+119例(90.2％),Ki-67+ 51例(38.6％).按照Fletcher分級,極低生物學風險者10例(7.6％),低風險者34例(25.8％),中風險者14例(10.6％),高風險者74例(56.1％).Fletcher風險分級極低風險患者的1、3、5年生存率均為100％,低風險患者均為97％,中風險患者均為92％,高風險患者分彆為96％、88％、83％,差異有統計學意義(P=0.028).完全切除+伊馬替尼組患者1、3、5年生存率均為100％,完全切除未服用伊馬替尼組患者均為99％,非完全切除+伊馬替尼組患者分彆為89％、65％、48％,差異有統計學意義(P＜0.05);不同解剖分區的胃間質瘤患者生存率差異無統計學意義(P＞0.05).結論 不同解剖部位的胃間質瘤患者預後無明顯不同,手術完整切除腫瘤和術後服用伊馬替尼可改善患者預後.
목적 탐토위간질류환자생존정황이급수술치료화약물치료대환자생존적영향.방법 회고성분석2003년1월지2013년1월구유완정병리급수방자료적132례원발위간질류환자적림상특점급생존정황.결과 132례환자술후중위수방22개월(1～83개월),1、3、5년적생존솔분별위99％、96％、92％.종류위우분문19례(14.4％),위저34례(25.8％),위대만38례(28.8％),위소만38례(28.8％),위두3례(2.3％).기중CD117+116례(87.9％),CD34+119례(90.2％),Ki-67+ 51례(38.6％).안조Fletcher분급,겁저생물학풍험자10례(7.6％),저풍험자34례(25.8％),중풍험자14례(10.6％),고풍험자74례(56.1％).Fletcher풍험분급겁저풍험환자적1、3、5년생존솔균위100％,저풍험환자균위97％,중풍험환자균위92％,고풍험환자분별위96％、88％、83％,차이유통계학의의(P=0.028).완전절제+이마체니조환자1、3、5년생존솔균위100％,완전절제미복용이마체니조환자균위99％,비완전절제+이마체니조환자분별위89％、65％、48％,차이유통계학의의(P＜0.05);불동해부분구적위간질류환자생존솔차이무통계학의의(P＞0.05).결론 불동해부부위적위간질류환자예후무명현불동,수술완정절제종류화술후복용이마체니가개선환자예후.
Objective To analyze the survival rates of gastrointestinal stromal tumors (GISTs),and the influence of surgical treatment and imatinib to the survival times.Methods The clinical data of 132 patients with GIST who were admitted to Peoples Liberation Army Hospital from January 2003 to December 2013 were retrospectively analyzed.Results All the patients were followed up with a median time of 22 months (1-83 months).The survival rates of 1-year,3-year,5-year were 99 ％,96 ％,92 ％ in this study.The tumor located at cardiac part,fundus of stomach,greater curvature,lesser curvature and pylorus part was 19 cases (14.4 ％),34 cases (25.8 ％),38 cases (28.8 ％),38 cases (28.8 ％) and 3 cases (2.3 ％),respectively.The positive rates of CD117,CD34 and Ki-67 was 116 cases (87.9 ％),119 cases (90.2 ％),51 cases (38.6 ％).According to Fletcher risk classification,the patients of high-low risk,low risk,intermediate risk,and high risk were 10 cases (7.6 ％),34 cases (25.8 ％),14 cases (10.6 ％),and 74 cases (56.1％),respectively.The differences of survive rates in the different excision method and imatinib treatment had statistics significance (P =0.000).The differences of survive rates in Fletcher risk classification had statistics significance (P =0.028).However,the differences of survive rates in location of gastric GIST showed no significant difference (P ＞ 0.05).Conclusions GIST in different parts of gastric have not obviously different survival rates,respectively.The total resection and imatinib treatment could raise the survival rates of patients with GIST.
